HSA
DNA icon

HBK Sorce Advisory’s Ginkgo Bioworks DNA Stock Holding History

HBK Sorce Advisory’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,000
Closed -$46K – 657
2022
Q4 		$46K Buy
1,000
+500
+100% +$46K ﹤0.01% 736
2022
Q3 		$22K Buy
+500
New +$59.6K ﹤0.01% 560

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

HBK Sorce Advisory's DNA Position: Q1 2023 in Review

HBK Sorce Advisory sold out of Ginkgo Bioworks (DNA) in Q1 2023, closing a stake of 1,000 shares — an estimated $46K sold.

HBK Sorce Advisory first reported a position in DNA in Q3 2022 and held it in 2 quarters. The position peaked at $46K in Q4 2022. 313 funds tracked by Wall St. Rank hold DNA as of Q1 2023.

  • HBK Sorce Advisory reported no remaining Ginkgo Bioworks position as of Q1 2023 after selling out during the quarter.
  • HBK Sorce Advisory sold 1,000 Ginkgo Bioworks shares in Q1 2023, an estimated $46K.
  • HBK Sorce Advisory first reported a position in Ginkgo Bioworks in Q3 2022 and held it in 2 quarters.
  • HBK Sorce Advisory's Ginkgo Bioworks position peaked at $46K in Q4 2022.
  • 313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2023.

Based on HBK Sorce Advisory's 13F filing for Q1 2023, filed 15 May 2023.